Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa | NEJM

https://www.nejm.org/doi/full/10.1056/NEJMc2119270#.Yc1RnRhgz0Q.twitter

SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron | medRxiv

https://www.medrxiv.org/content/10.1101/2021.12.26.21268380v1

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves | Global Health | JAMA | JAMA Network

https://jamanetwork.com/journals/jama/fullarticle/2787776?guestAccessKey=3ce0526a-20a1-4d9a-ba1b-0d26636a71da&utm_source=twitter&utm_medium=social_jama&utm_term=6139815954&utm_campaign=article_alert&linkId=146260188


Enviado desde mi iPhone

ALTA TASA DE ASINTOMATICOS CON OMICRON

https://www.medrxiv.org/content/10.1101/2021.12.20.21268130v1.full.pdf

SARS-CoV-2 Omicron VOC Transmission in Danish Households | medRxiv

https://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1

US officials recommend shorter COVID isolation, quarantine | AP News

https://apnews.com/article/coronavirus-pandemic-science-business-health-rochelle-walensky-d7d609c9c01e200d250df7ca7282c9d6?utm_campaign=SocialFlow&utm_source=Twitter&utm_medium=AP

COVID-19 vaccine breakthrough infections

https://www.science.org/doi/10.1126/science.abl8487

Saliva swabs are the preferred sample for Omicron detection | medRxiv

https://www.medrxiv.org/content/10.1101/2021.12.22.21268246v1

Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naïve and subjects recovered from COVID-19 - ScienceDirect

https://www.sciencedirect.com/science/article/pii/S2211124721017447


Enviado desde mi iPhone

Vacuna hetero trombosis

https://www.nejm.org/doi/pdf/10.1056/NEJMc2118507?articleTools=true


Enviado desde mi iPhone

The role of European health system characteristics in affecting Covid 19 lethality during the early days of the pandemic | Scientific Reports

https://www.nature.com/articles/s41598-021-03120-2

2021 in Review

https://www.medscape.com/viewarticle/963483?src=soc_tw_211225_mscpedt_news_mdscp_review&faf=1

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant: Cell

 

https://www.cell.com/cell/fulltext/S0092-8674(21)01496-3#relatedArticles

Ómicron: proponer soluciones – microBIOblog

https://microbioblog.es/omicron-proponer-soluciones

Neutralization and Stability of SARS-CoV-2 Omicron Variant | bioRxiv

https://www.biorxiv.org/content/10.1101/2021.12.16.472934v1

SAGE 99 minutes: Coronavirus (COVID-19) response, 16 December 2021 - GOV.UK

https://www.gov.uk/government/publications/sage-99-minutes-coronavirus-covid-19-response-16-december-2021/sage-99-minutes-coronavirus-covid-19-response-16-december-2021

Saliva is the Key Element for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mass Screening | Clinical Infectious Diseases | Oxford Academic

https://academic.oup.com/cid/article/73/3/e566/5933821

Saliva for molecular detection of SARS-CoV-2 in school-age children - PubMed

https://pubmed.ncbi.nlm.nih.gov/33618013/

Validation of an At-Home Direct Antigen Rapid Test for COVID-19 | Infectious Diseases | JAMA Network Open | JAMA Network

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783550

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel | NEJM

https://www.nejm.org/doi/full/10.1056/NEJMoa2106599?query=featured_home

Op-Ed: Pandemic fatigue has Americans glossing over Omicron. But we can't give up - Los Angeles Times

https://www.latimes.com/opinion/story/2021-12-16/omicron-infection-delta-complacency-hospitalization

‘No evidence’ Omicron is less severe than Delta, say UK researchers | Financial Times

https://www.ft.com/content/020534b3-5a54-4517-9fd1-167a5db50786

ECDC publishes new risk assessment on further emergence of Omicron variant

NO tiene desperdicio, dado el riesgo de la variante OMICRON ECDC convencido que solo con vacunas no vamos a llegar, publica estas recomendaciones.

https://www.ecdc.europa.eu/en/news-events/ecdc-publishes-new-risk-assessment-further-emergence-omicron-variant

Fwd: booster, Omicron, y otras bestezuelas del campo.

En este articulo el booster mejora el control de omicron y el que mas el utilizado con moderna. 

https://www.biorxiv.org/content/10.1101/2021.12.12.472269v1

Los comentarios en twitter de Tomas Pueyo causan bastante inquietud. Sobre si esta cepa altamente transmisible puede generar aunque menos letal (mortalidad relativa)un mayor  numero de casos, y mas mortalidad global.

https://unchartedterritories.tomaspueyo.com/p/the-omicron-question

Covid-19: Omicron and the need for boosters.

https://www.bmj.com/content/bmj/375/bmj.n3079.full.pdf

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant | medRxiv

https://www.medrxiv.org/content/10.1101/2021.12.14.21267769v1

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant | medRxiv

https://www.medrxiv.org/content/10.1101/2021.12.14.21267755v1

SINDROME CORONARIO

https://www.nps.org.au/assets/AP/pdf/p180-Eng-Frost-Chew.pdf

Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report | medRxiv

https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v2

Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults | medRxiv

https://www.medrxiv.org/content/10.1101/2021.11.19.21266555v1

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection: Med

https://www.cell.com/med/fulltext/S2666-6340(21)00382-2

Avances en gestión clínica: ¿Es posible evaluar los resultados de la integraci...

Avances en gestión clínica: ¿Es posible evaluar los resultados de la integraci...: Jordi Varela Editor La integración de servicios es una estrategia imprescindible para afrontar los retos que plantean las personas con neces...

SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021 | MMWR historia de 40 pacientes USA

sintomas y evolucion de 40 pacientes OMICRON

https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e1.htm?s_cid=mm7050e1_w

historia 7 pacientes sudafrica sintomas y evolucion.Breakthrough infections with SARS-CoV-2 Omicron variant despite booster dose of mRNA vaccine by Constanze Kuhlmann, Carla Konstanze Mayer, Mathilda Claassen, Tongai G. Maponga, Andrew D. Sutherland, Tasnim Suliman, Megan Shaw, Wolfgang Preiser :: SSRN

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3981711

eficacia y seguridad del booster

https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf

Effectiveness of a motivational intervention based on spirometry results to achieve smoking cessation in primary healthcare patients: randomised, parallel, controlled multicentre study

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458052/

Tercera dosis y proteccion mortalidad

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2115624?articleTools=true

good news vacunas covid tercera dosis

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2115926?articleTools=true

RV: peligrosos datos de Omicron.

---

 

https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection Sandile Cele1,2, Laurelle Jackson1, Khadija Khan1,2 ,David Khoury3, Thandeka Moyo-Gwete4,5, Houriiyah Tegally6,7, Cathrine Scheepers4,5, Daniel Amoako4, Farina Karim1,2, Mallory Bernstein1, Gila Lustig8, Derseree Archary8, Muneerah Smith9, Yashica Ganga1, Zesuliwe ... www.ahri.org

SARS-CoV-2 identified by transmission electron microscopy in lymphoproliferative and ischaemic intestinal lesions of COVID-19 patients with acute abdominal pain: two case reports | BMC Gastroenterology | Full Text

https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-021-01905-3

¿Por que me vacunan con Moderna II...?

Quizas este reciente articulo de Lancet da respuesta. Tanto si se basa de una pauta inicial doble de astra zeneca como si se trata de una pauta inicial doble de Pfizer parece que moderna es la que prodece una tasa mas alta de anticuerpos( resultado u output intermedio no de resultado final). Compara 7 tipos(vacunas diferentes o dosis) en el booster.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext#seccestitle160

Optimising SARS-CoV-2 vaccination schedules | Elsevier Enhanced Reader

https://reader.elsevier.com/reader/sd/pii/S0140673621017293?token=EC2CA37BA2124FD9942CBFC07289949C2200D2655050E1D93EFFFC6DB4D82601D60CF387243501DDFC85469BC8D0ECE7&originRegion=eu-west-1&originCreation=20211204130015

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - ScienceDirect

https://www.sciencedirect.com/science/article/pii/S0140673621016949?casa_token=yVkbsRtmQOMAAAAA:pAUo31cErIOzBg6lfLAXM5gcmZ6MhpfMhvarp1VeYDoZkLWQMn6CjQYroAh3C14qDg6Iu_KdDw

vacunacion heterologa inmunidad

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528081/pdf/nihpp-2021.10.10.21264827v2.pdf

¿Por que con moderna, si me vacune con Pfizer?

como muchos os estais preguntando en que se basan para la dosis recuerdo moderna:

Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel; perdida de inmunidad con el tiempo… de las vacunas

1. 
   

Https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1

1. 
   

1. 
   

2. ECDC. Interim public health considerations for the provision of additional COVID-19 vaccine doses. Technical report, 1 September 2021. 

   Initial studies have shown that an additional COVID-19 vaccine dose in immunocompromised individuals enhances antibody response. Several studies thus far have looked at seropositive responses with a third mRNA COVID-19 vaccine dose in immunosuppressed people. Among immunocompromised individuals who had no detectable antibody response following a full COVID-19 vaccination course, 33-50% developed an antibody response to an additional third dose [83-87].

   Disponible en: 

   https://www.ecdc.europa.eu/en/publications-data/covid-19-public-health-considerations-additional-vaccine-doses

   https://www.ecdc.europa.eu/sites/default/files/documents/Interim-public-health-considerations-for-the-provision-of-additional-COVID-19-vaccine-doses.pdf

   y 

   Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

   estudio hecho con Pfizer–BioNTech

   
   

   
   
   https://www.nejm.org/doi/10.1056/NEJMoa2114255

   68. Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int [Preprint]. 2021. DOI: 10.1016/j.kint.2021.06.025. Available at: https://www.sciencedirect.com/science/article/pii/S0085253821006554

       3 doses of BNT162b2 (Pfizer–BioNTech)

   69. Espi M, Charmetant X, Barba T, Pelletier C, Koppe L, Chalencon E, et al. Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study. medRxiv [Preprint]. 2021. DOI: 10.1101/2021.07.02.21259913. Available at: https://www.medrxiv.org/content/10.1101/2021.07.02.21259913v1

       BNT162b2, and the safety and impact on immune responses of a 3rd dose (3D).

   70. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021;385(7):661-2. Available at: https://www.nejm.org/doi/10.1056/NEJMc2108861

       three doses of the messenger RNA vaccine BNT162b2 (Pfizer–BioNTech).

   71. Longlune N, Nogier MB, Miedouge M, Gabilan C, Cartou C, Seigneuric B, et al. High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant [Preprint]. 2021. DOI: 10.1093/ndt/gfab193. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34057463

       three doses of the messenger RNA vaccine BNT162b2 (Pfizer–BioNTech).

   72. Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021 Available at: https://www.acpjournals.org/doi/full/10.7326/L21-0282 

       combinacion de vacunas RNA-jansen-etc.

    

   Recomendaciones de administración de dosis de recuerdo frente a COVID-19

   https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Dosis_de_recuerdo_frente_a_COVID_trasCSP_23nov2021.pdf

   
   

   Aprobado por la Comisión de Salud Pública, el 23 de noviembre de 2021 

   
   

   En ellas recomienda dosis recuerdo vacunas de ARNm (0,3 ml de Comirnaty o 0,25 ml de Spikevax independientemente de la vacuna utilizada en la primovacunación.

    no he encontrado ningun paper que avale o refute esta decisión. Esta reciente publicacion mezcla diferentes vacunas con buenos resultados de inmunogenicidad t efectos secundarios.
   

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext

3. Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford–AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer–BioNtech, hearafter referred to as BNT).
4. 
   

5. 
   

Opinión sanitaria : Cuál es la posibilidad de reinfección por la COVID...

Opinión sanitaria : Cuál es la posibilidad de reinfección por la COVID...:   Cuál es la posibilidad de reinfección por la COVID-19 y cuál es su evolución clínica Hace algunos días hablamos en el blog hermano “Qui pr...